Serentis pockets $20.6M in first round
The U.K.'s Serentis has ginned $20.6 million in its first round of venture capital. The money is being earmarked to push its lead candidates into proof of principle trials and provide the buying power to in-license new drug candidates. MVM Life Science Partners, Apposite Capital and Novo A/S jointly led the round for the Cambridge-based biotech, which was founded last year.
- check out the release for more information
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
